Clinical Trial Update: ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK [Phase 1, Phase 2]

View source ↗

Summary

The ROCKIF trial is investigating re-sensitization of carboplatin-resistant ovarian cancer using a focal adhesion kinase (FAK) inhibitor, in Phase 1 and Phase 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• FAK inhibitor (focal adhesion kinase inhibitor)

Snippet

Sponsor: Michael McHale | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: RECRUITING